https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-2022017-09-21 00:00:002019-02-15 08:45:45Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-21 / Int. J. Radiat. Oncol. Biol. Phys. 2018 01;100(1):78-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-21 / Int. J. Radiat. Oncol. Biol. Phys. 2018 01;100(1):78-872017-09-21 00:00:002017-09-21 00:00:00Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-21 / Blood Cells Mol. Dis. 2018 03;69:57-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-21 / Blood Cells Mol. Dis. 2018 03;69:57-642017-09-21 00:00:002017-09-21 00:00:00Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-692017-09-20 00:00:002019-02-15 08:36:14Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-19 / J. Biotechnol. 2017 Oct;260:91-972017-09-19 00:00:002017-09-19 00:00:00Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-2516
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-25162017-09-13 00:00:002017-09-13 00:00:00Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-12 / Clin. Immunol. 2017 10;183:181-190
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-12 / Clin. Immunol. 2017 10;183:181-1902017-09-12 00:00:002019-02-15 08:45:19Hematologic neoplasms: Dendritic cells vaccines in motion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-08 / Front Oncol 2017;7:195
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-08 / Front Oncol 2017;7:1952017-09-08 00:00:002019-02-15 09:23:13Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-2352017-09-01 00:00:002019-02-15 08:51:59Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-24 / Front Oncol 2017;7:179
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-24 / Front Oncol 2017;7:1792017-08-24 00:00:002017-08-24 00:00:00Oncolytic Viral Therapy for Mesothelioma
